Overview

A Study to Assess the Effect of a Single Infusion of VAY736 on Disease Activity in Patients With Relapsing-remitting Multiple Sclerosis

Status:
Terminated
Trial end date:
2018-09-13
Target enrollment:
Participant gender:
Summary
This was a randomized, partially blinded, placebo-controlled, non-confirmatory study to assess the effects of a single infusion of VAY736 on disease activity as measured by brain MRI scans in patients with relapsing-remitting multiple sclerosis (RRMS).
Phase:
Phase 2
Details
Lead Sponsor:
Novartis Pharmaceuticals